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resumo 
 
 
Doenças de sobrecarga lisossomal (DSL) são um grupo de doenças 
metabólicas hereditárias causadas pela acumulação de moléculas não 
degradadas nos lisossomas, devido sobretudo a defeitos em enzimas 
lisossomais. Mucopolissacaridoses são DSL caracterizadas pela acumulação 
de glicosaminoglicanos anteriormente designados mucopolissacarídeos. O 
foco deste trabalho é a Mucopolissacaridose tipo VI (MPS VI), que resulta da 
defeciência de uma hidrolase lisossomal (Arylsulfatase B) responsável pela 
degradação do sulfato de dermatan, o que leva á acumulação desta 
macromolécula nos doentes. O lisossoma é um organelo importante na 
apresentação de antigénios lipídicos ás células T. A apresentação de 
antigénios lipídicos é mediada por moléculas CD1 existentes nas células 
apresentadoras de antigénios. A ligação do antigénio lipídico ás moléculas 
CD1 das células apresentadoras leva á activação das células T restritas a CD1 
(NKT). Existem cinco isoformas de moléculas CD1 (a, b, c, d, e), mas apenas 
quatro são capazes de apresentar antigénios (a, b, c, d). Um dos locais na 
célula onde a associação das moléculas CD1 com os antigénios lipídicos 
ocorre é o lisossoma, portanto a apresentação de antigénios lipídicos pode 
estar afectada em doentes com DSL. Células NKT são um grupo heterogéneo  
de células T que partilham propriedades das células T e das células natural 
killer . Em humanos existem três subpopulações de células iNKT dependendo 
da expressão de CD4 e CD8: CD4+ (apenas expressam CD4), CD8+ (apenas 
expressam CD8) e duplas negativas (DN) que não expressam nenhumas das 
duas moléculas. Em estudos prévios foi observado em modelos animais de 
várias DSL uma diminuição na percentagem de células iNKT. Em doentes de 
Fabry e Gaucher não foram encontradas alteraçoes. O objectivo deste trabalho 
é estudar os linfócitos incluindo as células iNKT, as células dendríticas (como 
células apresentadoras de antigénios) e apresentação de antigénios lipídicos 
em doentes com MPS VI. Não foram encontradas alterações na percentagem 
de células iNKT assim como nas suas subpopulações entre doentes  com MPS 
VI e indivíduos controlos. Curiosamente encontramos um aumento na 
percentagem de linfócitos B em doentes com MPS VI quando comparados 
com indivíduos controlo. Para determinar o fenótipo das células dendríticas 
três doentes foram analisados, encontramos para alguns destes doentes uma 
diminuição na expressão das moléculas CD1a, CD11c e HLA-DR (MHC-class 
II), mas para tirar mas conclusões mais doentes precisam ser analisados. Três 
doentes com MPS VI foram analisados para testar a capacidade das suas 
células dendríticas apresentarem antigénios lipídicos pela molécula CD1b. Não 
foram encontradas alterações na capacidade destes doentes apresentarem o 
antigénio lipídico GM1 pela molécula CD1b. Pela primeira vez foram realizados 
ensaios de apresentação de antigénios lipídicos em doentes com MPS. 
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abstract 
 
Lysosomal storage diseases (LSD) are a group of hereditary metabolic 
disorders caused by accumulation of undegraded molecules in the lysosome, 
mainly due to the impairment of the function of lysosomal enzymes. 
Mucopolysaccharidoses are LSDs characterized by the accumulation of 
glycosaminoglycans previously designated Mucopolysaccharides. The focus of 
this work is the Mucopolysaccharidosis type VI (MPS VI), which is a disorder 
caused by a deficiency in a lysosomal hydrolase (Arylsulfatase B) responsible 
for the dermatan sulfate degradation, that leads to an accumulation of this 
macromolecule in the patients. Lysosome is an important organelle in the 
presentation of lipid antigen to T cells. Lipid antigen presentation is mediated 
by CD1 molecules existent in the antigen presenting cells. The binding of lipid 
antigens and the presenting cells containing CD1 molecules lead to activation 
of T cells that respond to those molecules.  There are five isoforms of CD1 
molecules (a, b, c, d, e), but only four are antigen presenting (a, b, c, d). One of 
the cell locations where the association of the CD1 molecules and lipid 
antigens occurs is the lysosome, so that means that antigen presentation could 
be affected in LSDs patients. NKT cells are a heterogeneous group of T cells 
that share properties with T cells and natural killer cells. In humans there are 
three subpopulations depending on the expression of CD4 and CD8 molecules: 
CD4+ (only express CD4), CD8+ (only express CD8) and double negative (DN) 
that do not express any of them. In previous studies a decrease in the 
percentage of iNKT cells were observed in mouse models of several LSDs. 
However in patients with Fabry and Gaucher diseases no alterations were 
found. The aim of this work is to study the lymphocytes including the iNKT 
cells, the dendritic cells (as antigen presenting cells) and the lipid antigen 
presentation in MPS VI patients. We found no alterations in the percentage of 
the iNKT cells and in their subsets between MPS VI patients and control 
subjects. Interestingly we found an increase in the percentage of the B 
lymphocyte population in MPS VI patients when compared with control 
subjects. For dendritic cells phenotype three patients were analyzed, we found 
for some of them a decrease of the expression of CD1a, CD11c and HLA-DR 
(MHC-class II) however, more patients need to be study before conclusions 
can be drawn. In lipid antigen presenting assays, three patients were tested for 
the capacity of their dendritic cells to present lipid antigens by CD1b molecule. 
We found nRDOWHUDWLRQVLQSDWLHQWVuFDSDFLW\WRSUHVHQWWKHOLSLGDQWLJHQ*0
by CD1b molecule. Studies regarding the lipid antigen presentation were for the 
first time performed in MPS. 
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1. Introduction 
1.1 Lysosomal storage diseases 
The lysosome was discovered in 1955, by Christian De Duve. The 
lysosome is an acidic organelle, containing many hydrolytic enzymes which are 
responsible for macromolecule degradation [1]. 
Lysosomal storage diseases (LSDs) are a group of metabolic disorders caused by 
a defect in lysosomal proteins, which normally result from a function defect of 
lysosomal enzymes (that is the case of Mucopolysaccharidoses) however can also 
be a result of a defect in a transport channel or regulatory protein (Niemann Pick 
type C disease). The dysfunction of those enzymes results in impaired substrate 
degradation and subsequently induces the accumulation of biological materials [2, 
3]. The accumulation of undigested macromolecules compromises the cell 
function, which can lead to an organ failure and in some cases early death [4]. 
LSDs are a group of more than 50 distinct genetic diseases [4]. They are 
individually rare, but when combined the prevalence estimated is 1 in 8000 births. 
The prevalence of those rare disorders has been studied in many countries. The 
frequency of LSDs in Portugal is 1 in 4000 [5], which is a high frequency when 
compared with other countries. In Australia the frequency is around 1 in 7700 
births [6]. In Netherlands the frequency reported is 1 in 7143 births [7], in Italy the 
prevalence of these disorders is 1 in 8264 births [8]. A recent study shows that the 
prevalence in Czech Republic is 1 in 8163 births [9].  
LSDs are classified according to the biochemical nature of the stored 
material into: lipidoses (mainly sphingolipidoses), mucopolysaccharidosis, 
glicogenoses, glycoproteinoses, neuronal ceroidlipofuscinoses and mucolipidoses 
[2]. 
Pompe disease was the first recognized LSD, this disease is characterized 
by the accumulation of glycogen in the lysosome. It was first described  in 1932, 
prior to the discovery of the lysosome [4]. In the year of 1963, this glycogen 
VWRUDJH GLVHDVH ZDV DVVRFLDWHG ZLWK D GHIHFW LQ WKH O\VRVRPDO HQ]\PH Į-
glucosidase, and so recognized as an LSD [10]. 
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               1.1.1 Mucopolysaccharidoses 
 
The Mucopolysaccharidoses (MPS) are a group of lysosomal storage 
disorders caused by deficiency of specific lysosomal enzymes that catalyze the 
degradation of glycosaminoglycans (GAGs) previously called 
mucopolysaccharides. GAGs with the exception of hyaluronic acid are degraded 
products of proteoglycans which exist in the extracellular matrix. The GAGs enter 
in the lysosome for intracellular digestion. In MPS the undegraded or partially 
degraded GAGs are stored in lysosomes, this accumulation in various organs of 
patients, results in several organ dysfunctions, which lead to a multisystemic 
clinical picture [11, 12].  
Lysosomal degradation of GAGs has different pathways depending on the 
molecule to be degraded: dermatan sulfate, heparan sulfate, keratan sulfate and 
chondroitin sulfate. This process requires ten different enzymes: 4 
exoglycosidases, 5 sulfatases and 1 monhydrolytic transferase [12].  
Patients with MPS have GAGs degradation impaired, although the 
presentation of GAGs to lysosome for degradation occurs normally which cause a 
continuous storage that gives rise to an enlargement of the lysosomes. The 
increase of the size and impaired function of lysosomes could compromise other 
cellular organelles [12].   
The different types of MPS share many clinical features in variable degrees. 
Those include a chronic and progressive course, multisystem involvement, 
organomegaly, dysostosis multiplex and facial dysmorphia. Hearing, vision, 
airway, cardiovascular function and joint mobility may be affected. Profound 
mental retardation is a characteristic of MPS I, the severe form of MPS II and all 
subtypes of the MPS III, in other MPS normal intellect may be retained [11]. 
The enzymatic defects that lead to the diverse MPS types and the main 
substrates accumulated are described in Table 1. 
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Table 1. Mucopolysaccharidoses: defective enzyme and accumulated substrates.  
Disease Subtype Enzyme deficiency Accumulated GAG 
 
MPS I 
Hurler 
 
 
Hurler-Scheie 
 
Scheie 
g-L-iduronidase 
 
 
g-L-iduronidase 
 
g-L-iduronidase 
Dermatan and 
heparan sulfate 
 
 
Dermatan and 
heparan sulfate 
 
Dermatan and 
heparan sulfate 
 
MPS II 
(Hunter) 
 
 
 
Irudonate sulfatase 
 
Dermatan and 
heparan sulfate 
 
 
 
MPS III 
Sanfilippo A 
 
Sanfilippo B 
 
Sanfilippo C 
 
 
Sanfilippo D 
Heparan-N-sulfatase 
 
 
g-N-Acetyl-
glucosaminidase 
 
Acetyl-CoA:g-
glucosaminide 
acetyltransferase 
 
N-acetylglucosamine 6-
Sulfatase 
Heparan Sulfate 
 
Heparan Sulfate 
 
Heparan Sulfate 
 
 
Heparan Sulfate 
 
MPS IV 
 
Morquio A 
 
Morquio B 
 
Galactose 6-sulfatase 
 
く-galactosidase 
 
Keratan and 
chondroitin sulfate 
 
Keratan sulfate 
MPS V This designation is no longer used 
 
MPS VI 
(Maroteaux-Lamy) 
  
Arylsulfatase B 
N-acetylgalactosamine 4-
sulfatase 
 
Dermatan sulfate 
 
MPS VII 
(Sly) 
  
く-glucuronidase 
Dermatan, keratan 
and chondroitin 
sulfate 
MPS VIII This designation is no longer used 
MPS IX  Hyaluronidase Hyaluronan 
 
The focus of this study is Mucopolysaccharidosis type VI, which is 
described in the following section. 
 
 6 
 
                   1.1.1.1 Mucopolysaccharidosis VI 
Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive MPS, 
which results from a deficiency of arylsulfatase B also called N-
acetylgalactosamine 4-sulfatase. MPS VI is also known as Maroteaux-Lamy 
syndrome named in 1963 after Dr. Pierre Maroteaux and Dr. Maurice Lamy that 
first described this disease [13]. Arylsulfatase B (ASB) is a lysosomal enzyme that 
removes the sulfate group from the dermatan sulfate GAG [12], the degradation 
pathway of dermatan sulfate are represented in Figure 1.  Reduced or absent 
activity of the ASB lead to an incomplete degradation and cellular accumulation of 
the dermatan sultafe, causing cell injury [14]. 
 
Figure 1. Degradation pathway of dermatan sulfate, (A) represents the step that 
causes the MPS VI deficiency. Image adapted from [11]. 
 
The estimated prevalence of MPS VI in north Portugal is 1 in 238 095 live 
births [5], in Australia is 1 in 248 372 live births, but in north countries like Sweden 
or Norway the prevalence is really low comparing with other counties, is 1 in 1 505 
160 live births in Sweden and 1 in 1 455 813 live births in Norway [14]. 
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Molecular basis 
MPS VI is an autosomal recessive disorder resulting from the mutations in 
the gene encoding the ASB enzyme (ARSB), which is located in chromosome 5 
contain 8 exons and span about 206 Kb [11, 12]. To date, there are more than 130 
described mutations in Human Gene Mutation Database including nonsense and 
missense mutations, which are the most common mutations in this pathology, in 
addition can happen splicing mutations, deletions and insertions [14]. 
 
Clinical Manifestations 
The characteristic symptoms of MPS VI are: hearing and visual impairment, 
which can lead to a loss of hearing and blindness; upper airway obstructions and 
enlargement of the tongue, which can cause asphyxia; skeletal deformities and 
compromised growth; nervous system disorders including hydrocephalus, spinal 
cord disorders and compressive neuropathies, but normal intelligence. Frequently 
poor clearance of airway secretions leads to a recurrent pneumonia.  The most 
common cause of death of these patients are cardiac diseases caused by 
abnormal storage of dematan sulfate in the heart and blood vessels [13, 14]. 
The severity of clinical manifestation of MPS VI depends of the onset age 
and rate of the disease progression. The rapid progress of the disease is 
characterized by high levels of GAGs in urine, between 100 and 200µg/mg 
creatinine.  In most cases the onset is before 2 or 3 years of age, symptoms 
include impaired mobility by 10 years old, absent or delayed puberty, cervical 
spinal cord compression, respiratory insufficiency and surgical complications. 
Patients frequently die from heart complications at 20 or 30 years.  The slow 
progress is characterized by levels of GAGs in urine lower than 100µg/mg 
creatinine and in this case the symptoms have a later onset and the diagnosis 
generally occurs after 5 years of age. These patients eventually develop serious 
manifestations, such as joint degeneration, cardiac valve disease, sleep apnea, a 
decrease in pulmonary function and reduced endurance [14]. 
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Diagnosis 
Diagnosis is necessary to distinguish between type VI and other types of 
MPS, because they share similar symptoms. The diagnosis can include evidence 
of clinical phenotype, analysis of GAGs quantity in urine and analysis of ABS 
enzyme activity in isolated leukocytes, cultured skin fibroblasts or in dried blood 
spot this activity is generally less than 10% of the lower limit of normal ABS activity 
[13, 14]. The biochemical diagnosis in our laboratory is done by measurement of 
the ABS enzyme activity in dried blood spot and genotypic alterations were 
identified by DNA sequencing. 
 
Treatment 
The main focus of the treatment of MPS before the use of recent therapies 
like enzyme replacement therapy was to prevent complications and to improve the 
quality of life in the patients. This first treatment was symptomatic and palliative, 
based on a multidisciplinary team with diverse clinical specialties, including 
nutrition counseling, occupational and physical therapy and management of 
individual symptoms. Surgical intervention may be needed, depending on the 
severity of the symptoms [14, 15]. 
Bone marrow transplantation has been used in rare cases, because the risk 
of death, morbidity and difficulty obtaining adequate or optimal HLA-matched 
donors [14]. 
Enzyme replacement therapy for the treatment of MPS VI is available since 
2005, and is performed by intravenous administration of Naglazyme (galsulfase) a 
recombinant form of the enzyme ASB. Naglazyme can be administered to all 
symptomatic patients [15]. The patients under this therapy reveled endurance 
improvement and a decrease of GAGs level in urine [16]. 
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1.2 Presentation of lipid antigens to T cells 
 
The presentation of lipid antigen to T cells is mediated by CD1 molecules 
present at the surface of antigen presenting cells (APCs). The lipid antigen bound 
with CD1 molecules is recognized by the T cell receptor (TCR) that causes the 
activation of T cells, which leads to their proliferation, cytokine production and in 
some cases cytolytic activity. A design of this process is shown on Figure 2. 
 
 
 
Figure 2. Activation of CD1-restricted lipid-specific T cells by dendritic cells. 
 
 
   1.2.1 The nature of lipid antigens 
The lipid antigens can be divided in two groups, the self lipid antigens that 
have origin in the body and the non-self that originate from external microbial or 
environmental sources. Lipid antigens can also be classified depending on the 
location of synthesis, as endogenous if they are synthesized in the same APC that 
interacts with the T cells or exogenous if they are synthesized in other cells and 
then transferred to the APC [17]. Mycobacteria, Spingomonas, Ehrlichia and 
Borrelia are examples of bacteria for which were identified lipid antigens [17].  The 
Į-JDODFWRV\OFHUDPLGH Į-GalCer) is the non-self lipid antigen most potent and 
studied, and was originally isolated from the Agelas mauritianus sponges [18]. The 
great majority of identified lipid antigens are glycosphingolipids. Several 
glycosphingolipids of self origin were identified as lipid antigens, such as GM1, 
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VXOIDWLGH *' DQG ȕ-D-glucopyranosylceramide C24:1 [19, 20]. Mono-alkyl 
glycerophosphates were recently identified as an important lipid family that 
contributes to the maturation of iNKT cells [21].  
 
   1.2.2 CD1 molecules 
The CD1 molecules are MHC class I-like glycoproteins composed by a 
heavy and a light chaLQ7KHKHDY\FKDLQZKLFKLVWKHĮFKDLQLVGLYLGHGLQWKUHH
H[WUDFHOOXODUGRPDLQVĮĮDQGĮ7KHĮGRPDLQLVQRQFRYDOHQWO\DVVRFLDWHG
ZLWK ȕ-micoglobulin which corresponds to the light chain of the CD1 molecule. 
7KH Į DQG Į GRPDLQV DUH RUJDQL]HG LQ WZR Į-helices and compose the lipid 
antigen binding pocket [22, 23].  
 
CD1 expression 
CD1 molecules are expressed by a variety of cell types including dendritic 
cells (DCs), B cells, monocytes, Langerhans cells, stellate hepatic cells, epithelial 
cells, microglial cells and keratinocytes.  Mice only have one isoform, the CD1d, 
although in humans five CD1 genes have been identified on chromosome 1. 
These genes encode CD1 proteins that represent distinct CD1 isoforms, which are 
CD1a, CD1b, CD1c, CD1d and CD1e [23, 24]. These isoforms can be divided in 
three groups according to homology of the Į DQG Į GRPDLQV *URXS , LV
composed by CD1a, CD1b and CD1c isoforms, group II by CD1d and group 3 by 
CD1e [19]. The CD1e isoform is involved in lipid antigen processing, but this 
isoform does not reach the cell surface and consequently is not involved in lipid 
antigen presentation [23].  
 
CD1 synthesis and trafficking 
The CD1 proteins are synthesized in the endoplasmatic reticulum (ER) and 
in this organelle the glycosylation is initiated. The following process is the 
DVVRFLDWLRQ RI ȕ-PLFURJOREXOLQ ZLWK &' Į FKDLQ 7KH FRUUHFW IROGLQJ RI &'
proteins is assisted by the interaction with chaperone proteins such as calnexin, 
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calcireticulin and ERp57 [23]. Endogenous lipids in the ER bind CD1 molecules 
during assembly and probably prevent their collapse [24].  
After being synthesized in the ER CD1 molecules migrate to the Golgi 
apparatus where the glycosylation process is completed, and then move to the cell 
surface with exception of CD1e [23].  
Some potent lipid antigens can be presented by the CD1 isoforms at the 
cell surface. However, for presentation of other lipid antigens, CD1 molecules 
need to be internalized, following the endocytic pathway [19]. CD1 isoforms 
pathways are described in Figure 3. 
 
 
Figure 3. CD1 isoforms are transported through the Golgi and trans Golgi network 
(TGN) to reach the cell surface, with the exception of CD1e, which remains in the cell. Image 
from [25]. 
 
 
   1.2.3 CD1 molecules loading with lipid antigens 
Lipids are poorly soluble in water, so they need to form a complex with 
SODVPD OLSRSURWHLQV ZKLFK IDFLOLWDWH WKHLU XSWDNH E\ $3& 7KH KLGURODVHV Į-
galactosidade A, hexosaminidase B and acidic Į-mannosidase are involved in 
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partial degradation of complex glycolipid antigens. This degradation is needed for 
the binding of lipids containing large hydrophilic moieties to CD1 molecules [24].  
Lipid transfer proteins (LTPs) such as saposins, GM2-activator protein and 
Niemann-Pick C2 protein facilitate the extraction of lipids from lysosomal 
membranes and loading in CD1 molecules [24, 26]. CD1e is also an LTP required 
for the processing of complex mycobacterial antigens [27]. Another LTP with 
immunological relevance is the microssomal triglyceride transfer protein which has 
been shown to regulate the loading of self-lipids onto CD1 molecules in the ER 
[26, 28]. Besides LTPs other factor that facilitates the loading of lipid antigens onto 
CD1 molecules is the low pH present in the lysosome [28]. 
 
   1.2.4 CD1-restricted T cells 
CD1-restricted T cells have a TCR that recognize the CD1 molecules at the 
surface of an APC.  These CD1-restricted T cells are classified in two groups 
according to the CD1 isoforms to which they are restricted.  
 
Group I CD1-restricted T cells 
Group I includes T cells restricted to CD1a, CD1b and CD1c, which can 
H[SUHVVDĮȕRUȖį7&5 Group I restricted T cells can express at the surface CD4 
(CD4+), CD8 (CD8+) or neither of the molecules, being CD4-CD8 double negative 
(DN). Group I CD1-restricted T cells can release different types of cytokines, 
including Th1, Th2 and Th17 cytokines [17]. 
In the peripheral blood of healthy adults the CD1a restricted T cells are the 
most frequent, followed by CD1c, CD1d and CD1b restricted T cells which are the 
least frequent [29, 30]. 
 
Group II CD1-restricted T cells 
The group II is composed by CD1d-restricted T cells, which include two 
populations of natural killer T (NKT) cells. NKT cells express markers of the 
natural killer (NK) cells and the TCR. Two populations are divided according to the 
TCR properties. The first population Type I NKT cells, includes T cells that express 
 13 
 
a semi-invariant TCR and are called as invariant NKT (iNKT) cells. The second 
SRSXODWLRQ7\SH ,,1.7FHOOVKDYHYDULDEOHĮDQGȕFKDLQV [17]. The iNKT cells 
KDYH D 7&5 ZLWK VSHFLILFLW\ IRU JOLFROLSLG DQWLJHQV OLNH WKH JO\FRVSKLQJROLSLG Į-
GalCer. Because of the invariant chain and this specificity, the iNKT cells can be 
GHWHFWHG ZLWK Į-GalCer-loaded CD1d tetramers. Type II NKT cells recognize 
hydrophobic antigens including sulfatide and lysophosphatidylcholine [31]. 
Little information is available about Type II NKT cells because they are 
difficult to identify. Due to the variable TCR it is hard to found surface markers to 
identify these cells. Therefore the study of CD1d-restricted T cells is centered in 
iNKT cells, because they can be identified by the use of CD1d tetramers. 
 
iNKT cells 
iNKT cells are cytotoxic T lymphocytes with a TCR that in humans is 
FRPSRVHGE\DQ9Į-ĮFKDLQFRPELQHGZLWKDOLPLWHGEXWQRWLQYDULDQWȕFKDLQ
UHSHUWRLUHPRVWXVXDOO\LV9ȕ[32]. iNKT cells are capable of modulate immunity 
responses in a broad spectrum of diseases, by the production of a broad range of 
cytokines. These cells are associated with protective and regulatory functions in 
tumor surveillance, chronic infectious diseases, transplants and autoimmunity  
[31]. And a role in the pathogenesis of inflammatory bowel diseases and in asthma 
was also described [33]. Other study shows that in cases of HIV infection and 
Mycobacterium tuberculosis infection iNKT cells had phenotypes associated with 
immune activation, and the absolute number of these cells was reduced in 
peripheral blood [34]. 
iNKT cell numbers are highly variable in humans. The number can range 
from 0.001% to over 3% of blood lymphocytes [31]. The iNKT cells in humans can 
be divided in three functional subsets, the CD4+, CD8+ and CD4-CD8- DN. In the 
human thymus the iNKT cells are mainly CD4+.  The CD4-CD8- DN and CD8+ are 
highly proliferating cells in the periphery [35].  
iNKT cell development begins in the thymus with the expression of the 
invariant TCR. In the differentiation pathway cells are positively selected by the 
interaction of the TCR with CD1d molecules expressed by thymocytes. In mice, 
the iNKT cells maturation has at least four stages. Stage 0, which is characterized 
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by a population CD24-positive, CD44loNK1.1lo, in this stage the cells are extremely 
rare and are not proliferating. After CD24 downregulation the cells start to 
proliferate, this is stage 1 where the cells are CD24loCD44loNK1.1lo. The cells 
continue to proliferate and start to maturate. As they maturate they upregulate 
CD44 entering in stage 2 where the cells are CD24loCD44hiNK1.1lo. The last 
maturation phase, stage 3 is defined by upregulation of NK cell markers such as 
NK1.1 and is accompanied by much less proliferation as they migrate to the 
periphery. In humans, iNKT cell maturation is also completed at the periphery. The 
earliest detectable iNKT cell precursors are CD4+ and CD161lo (human equivalent 
to NK1.1) these cells leave the thymus in this stage and continue their maturation 
in the periphery, were they become CD4-CD161+. Mature iNKT cells are extremely 
rare in human thymus, in contrast to their frequency in human blood [31]. 
iNKT cells are activated in the presence of endogenous and exogenous 
antigens loaded in CD1d molecules. This activation process may occur by three 
different pathways. The first one is foreign antigen-driven pathway were the 
antigen can be internalized and loaded in CD1d molecules or directly loaded in 
CD1d molecules at the cell surface. This complex CD1d-lipid antigen present at 
the surface of the APC interacts to the TCR of the iNKT cell, causing its activation. 
The second one is cytokine and self-antigen-driven pathway. In this case the 
antigens bind to toll-like receptors (TLRs) present at the surface of the APC 
promoting the loading of endogenous antigens in CD1d molecules and IL-2 
secretion, causing double activation of the iNKT cells. In the third case, dominantly 
cytokine-driven pathway the antigens that bind to the TLRs promotes IL-2 
secretion by the APCs, without the need for additional TCR-mediated stimulation 
[36]. 
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1.3 CD1-restricted T cells in Lysosomal storage diseases 
The lysosome is an important organelle in lipid antigen presentation by CD1 
molecules, and therefore important to the CD1-restricted T cells. In patients with 
LSDs the function of the lysosome is impaired and so the lipid antigen 
presentation could be affected. This impairment of the lipid antigen presentation 
can lead to an alteration of the CD1-restricted T cell population. The majority of the 
studies regarding lipid specific CD1 restricted T cells in LSDs were performed in 
mice analyzing the iNKT cells. It was described for several mouse models of LSDs 
a decrease of the percentage of iNKT cells in the thymus and at the periphery. 
These studies showed a decrease of the iNKT cell percentage in mouse models of 
Sandhoff disease [37-39], GM1 gangliosidosis [37, 40], Niemann Pick C1 [37, 41], 
Tay-Sachs disease [37], Multiple sulfatase deficiency [39], and Fabry disease[37, 
42, 43]. On the other hand, metachromatic leukodystrophy, Krable disease and 
MPS I presented no alterations in the frequency of iNKT cells [39]. Those results, 
that show a reduction in iNKT cells raise a question, of this happened due to a 
specific defect that leads to an accumulation of a specific lipid or simply arise from 
a non-specific effect of macromolecules accumulation in the lysosome. 
  In humans, both patients with Fabry and Gaucher diseases were analyzed 
regarding iNKT cell percentage. In Fabry disease patients no alterations on the 
iNKT cell percentage were found [42, 44] however, a difference in the subset CD4+ 
was observed in a previous work (Cátia Pereira et al unpublished results). In 
Gaucher disease patients no alterations on the percentage of iNKT cells were 
found too [45]. 
The capacity of APCs from LSDs mouse models to present lipid antigens to 
iNKT cells was tested, to identify the cause of this reduced percentage of iNKT cell 
population in LSDs. In the mouse models tested of Sandhoff, Fabry, GM1 
gangliosidosis, NPC1 deficiency and NPC2 deficiency the decrease in the number 
of iNKT cells was confirmed to be associated with deficient lipid antigen 
presentation [37, 38, 40, 41, 43, 46]. 
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2. Aims 
 
Considering the previous studies that found alterations in the iNKT cells 
percentage and in lipid antigen presentation in mouse models of LSDs, the aim of 
this work was to study the effects of metabolic alterations in 
Mucopolysaccharidosis type VI lymphocytes including iNKT cells and in lipid 
antigen presentation. The more specific aims were: 
x To quantify the lymphocytes in Mucopolysaccharidosis type VI patients 
x To quantify the iNKT cells and subsets in Mucopolysaccharidosis type VI 
patients 
x To assess the phenotype of Mucopolysaccharidosis type VI patients 
dendritic cells 
x To test the capacity of dendritic cells from Mucopolysaccharidosis type VI 
patients to present lipid antigens by the CD1b isoform. 
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3. Methods 
All the experimental analyses were performed using peripheral blood 
samples from MPS VI patients and control subjects. PBMCs were isolated and 
used for: 
o Flow cytometry analyses, to study the lymphocyte population; 
o Dendritic cell generation. 
For five of the patients, the first of the two determinations were performed 
by Dr. Fátima Macedo and Cátia Pereira prior to the start of this thesis. Dendritic 
cells were cultured for 7 days and then analyzed by flow cytometry to confirm the 
success of the differentiation and to assess CD1, MHC-class I and MHC-class II 
cell surface expression, or used in antigen presentation assays. In these assays, 
dendritic cells were incubated with different concentrations of lipid antigen and a T 
cell clone restricted for CD1b molecule. The capacity of antigen presentation was 
evaluated by the amount of GM-CSF produced by the activated T cell and 
measured by enzyme linked immunosorbent assay (ELISA). Experimental design 
of the study is described in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Experimental design of the study. 
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Subjects and sample collection 
Seven MPS VI patients and seven control subjects were analyzed in this 
study. The MPS VI patients group was composed by five females and two males. 
In the control group, there were five females and two males. Control subjects were 
blood donors at the Centro Regional de Sangue do Porto ± Instituto Português do 
Sangue (IPS), at the Hospital São João do Porto or at the Hospital de Santo 
António do Porto. Samples were obtained under a protocol between IBMC and 
these institutions. MPS VI patients were recruited by their physicians, Dr. Elisa 
Leão Teles from Hospital São João and Dr. Esmeralda Martins from Hospital de 
Santo António. In the beginning of this study, all the patients were already under 
ERT. This treatment consists in the administration of a recombinant form of the 
ASB enzyme (Naglazyme) via regular intravenous infusions. The characteristics of 
the patients included in the study are described in the results section 4, on table 4. 
 
Peripheral blood mononuclear cells (PBMCs) isolation 
After the samples arrive, PBMCs were isolated using density gradient 
centrifugation with Histopaque-1077 from Sigma, under sterile conditions. The 
blood was layered on an equal amount of Histopaque-1077 and centrifuged at 
400xg for 30 minutes without brake. After the centrifugation, the PBMCs are 
located in a ring between plasma and Histopaque-1077. PBMCs were then 
collected and washed once by adding 10mL of phosphate buffered saline 1x (PBS 
1x, see appendix) and centrifuged at 250xg for 10 minutes. Then the remaining 
erythrocytes were lysed by incubating cells for 10 min with 15mL of ACK lysis 
solution (see appendix). Cells were washed once more with 10mL of PBS 1x and 
counted using a Neubauer chamber. After cell count, PBMCs were used for flow 
cytometry or for dendritic cell differentiation. 
 
Flow Cytometry 
Up to 1 x 106 PBMCs or about 0.05 x 106 dendritic cells were stained per 
well in a round-bottomed 96-well plate. To use few dendritic cells 0.5 x 106 of 
Jurkat cells were added per well and we used an anti-human CD3 antibody to 
exclude the Jurkat cells in our analyses. The cells were added to the plate, and 
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then centrifuged at 1200 rpm for 2 min. For PBMCs, supernatant was rejected and 
the cells were resuspended in 25µL of the antibody/tetramer mix diluted in PBS 
0.2% BSA 0.1% NaN3 (flow cytometry solution, see appendix). The antibodies 
listed in Table 2 were used. 
 
Table 2. Antibodies used in PBMCs flow cytometry to identify the T cells, B cells and 
NK cells population. 
Antibody Clone Flourochrome Brand 
Anti-human CD3 SK7 PerCP-Cy5.5 eBioscience 
Anti-human CD4 RPA-T4 PE-Cy7 eBioscience 
Anti-human CD8 RPA-T8 APC-eFluor 780 eBioscience 
Anti-human CD19 HIB19 PE-Cy7 eBioscience 
Anti-human CD56 MEM188 FITC eBioscience 
APC-eFluor 780 ± Allophycocyanin conjugated with eFluor 780; PE-Cy7 ± Phycoerythrin 
conjugated with Cy7; PerCP-Cy5.5 ± Peridinin chlorphyll protein conjugated with Cy5.5; FITC ± 
Fluorescein. 
 
 
To identify iNKT cells, the CD1d tetramer loaded with PBS57 and labeled 
with the flourochrome phycoerythrin (PE), from National Institute of Health 
tetramer core facility ZDV XVHG 3%6 LV DQ DQDORJXH RI Į-GalCer, that was 
VKRZQ WR KDYH LQGLVWLQJXLVKDEOH DFWLYLW\ IURP Į-GalCer being the CD1d-PBS57 
tetramer capable of effectively detect both mouse and human iNKT cells [47]. An 
unloaded CD1d tetramer was used as a control to identify unspecific staining. 
For dendritic cells flow cytometry is needed one more step because they 
need to be blocked to avoid unspecific staining, so they were resuspended in 50µL 
of PBS 25% human serum (see appendix) and incubated for 20 min at 4ºC. Then 
dendritic cells were washed twice by adding 100µL of flow cytometry solution and 
centrifuged at 1200 rpm for 2 min. After that, 25µL of the antibody mix were added. 
The antibodies used for dendritic cell staining are described in Table 3. 
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Table 3. Antibodies used in dendritic cells flow cytometry to confirm differentiation 
and to assess CD1, HLA-ABC (MHC-class I) and HLA-DR (MHC-class II) expression. 
Antibody Clone Fluorochrome Brand 
Anti-human CD1a HI149 PE eBioscience 
Anti-human CD1b SN13 FITC Biolegend 
Anti-human CD1c L161 PerCP Biolegend 
Anti-human CD1d CD1d42 PE BDBioscience 
Anti-human CD11c 3.9 PE-Cy7 eBioscience 
Anti-human HLA-ABC W6/32 FITC eBioscience 
Anti-human HLA-DR LN3 APC eBioscience 
Anti-Human CD80 2D10 APC Biolegend 
PE ± Phycoerythrin; FITC ± Fluorescein; PerCP ± Peridinin chlorphyll protein; PE-Cy 7 ± 
Phycoerytrin conjugated with Cy7; APC ± Allophycocyanin. 
 
Both PBMCs and dendritic cells were incubated for 20 min at 4ºC, in the 
dark. After incubation, PBMCs were washed three times by adding 100µL of flow 
cytometry solution, centrifuged at 1200 rpm for 2 min, rejected supernatant and 
resuspended cells. After the last wash, PBMCs were resuspended in 350µL of 
PBS 1% formaldehyde (see appendix) and dendritic cells were washed twice and 
resuspended too in 350µL of PBS 1% formaldehyde. All samples were transferred 
to FACS tubes (BD bioscience).  
For PBMCs (iNKT cells), up to 2000 events were acquired inside the gate of 
iNKT cells, and for B cells, up to 10000 events were aquired in a FACSCanto (BD 
bioscience), using the FACSDiva software (BD bioscience). In the case of 
dendritic cells, 10000 events were acquired using the same equipment and 
software used for PBMCs. All flow cytometry analyses were done using the 
FlowJo software (Tree Star). 
 
Dendritic cell differentiation 
PBMCs include lymphocytes and monocytes. Dendritic cells can be 
differentiated in vitro from peripheral blood monocytes, so it was necessary to 
separate these two cell types. Immunomagnetic labeling using MACS anti-human 
CD14 MicroBeads from Miltenyi Biotec were used to achieve this separation. The 
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technique uses magnetic beads bound to an anti-human CD14 antibody that 
attaches to the monocytes, which are CD14+ cells (Figure 5). 
 
 
 
 
Figure 5. Separation of CD14+ cells by positive selection using MACS beads. Figure 
adapted from http://www.proimmune.com 
 
PBMCs were washed once with 5mL of 1x PBS 2mM EDTA 0.5% BSA 
(MACS buffer, see appendix). Then, they were centrifuged at 1800 rpm for 5 min 
and the supernatant was rejected. Cells were resuspended in MACS buffer and 
incubated with the anti-human CD14 magnetic beads on ice, for 20 min, in the 
dark, with occasional shaking. In this step the anti-human CD14 antibodies 
present in the magnetic beads bind to the monocytes. The amount of MACS buffer 
and magnetic beads used depended on the total number of cells in the solution, 
according to the following proportion: for 100 x 106 of PBMCs, use 475µL of MACS 
buffer and 62.5µL of anti-human CD14 magnetic beads. For few cells (less than 20 
x 106) the proportion changes to: for 10 x 106 of PBMCs, use 80µL of MACS buffer 
and 20µL of anti-human CD14 magnetic beads. After incubation, cells were 
washed twice with 5mL of MACS buffer. The columns (can be MS or LS) are 
chosen depending on the number of PBMCs available. According to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV06FROXPQVZHUHXVHG LI WKHUHZHUH OHVV WKDQ[
106 PBMCs available and LS columns if there were more. The columns were 
placed in the magnetic support and pre-wetted with MACS buffer. The magnetic 
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force existent between the beads and the support keeps the labeled cells from 
eluting.  For LS columns, the cells were resuspended in 4mL and for MS columns 
the cells were resuspended in 0.5mL of MACS buffer and applied. The monocytes 
that bond to the magnetic beads remained in the column, while the non-labeled 
cells are eluted. The columns were washed by loading 4mL or 0.5mL of MACS 
buffer three times. This step is important to remove from the column cells that are 
not bound to the magnetic beads, increasing the efficiency of the separation. The 
columns were removed from the magnetic support and placed in 15mL falcon 
tubes. Depending on the columns used, 4mL or 1mL of MACS buffer were loaded 
in the column and then cells were flushed from the column to a 15mL falcon tube, 
by applying the plunger, supplied with the column. Finally the CD14+ cells are 
eluted, since the column is no longer in the magnetic support. After the isolation 
process, cells were counted and plated at 1 x 106/mL in six-well plates, 3mL per 
well in dendritic cell culture medium, RPMI 10% heat inactivated fetal bovine 
serum (iFBS), containing 25ng/mL of recombinant human interleukin 4 (rhIL-4 from 
ImmunoTools) and recombinant human granulocyte macrophage-colony 
stimulating factor (rhGM-CSF from ImmunoTools). Cells were incubated at 37ºC, 
5% CO2. At day 4 of culture, medium was refreshed by removing 500µL of culture 
medium per well and by adding 500µL per well of dendritic cell medium with a 
higher concentration of cytokines (75ng/mL of rhIL-4 and 75ng/mL of rhGM-CSF). 
Cells were used for activation assays and flow cytometry at day 7. 
 
T cell clone 
T cell clone used for the lipid antigen presentation assays were kindly 
provided by Prof. Gennaro De Libero from Basel University, Switzerland. T cell 
clone was established and maintained as described [48, 49]. Briefly, T cell lines 
were produced by the stimulation of PBMCs with autologous dendritic cells that 
had been pre-incubated with a mixture of glycolipids [48]. After 3 weeks, growing T 
cells were restimulated with heterologous dendritic cells plus the mixture of 
glycolipids. T cell clone were obtained by limiting dilution and scored for antigen 
specificity and CD1 restriction using CD1-transfected APCs [48, 49]. In this study 
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the T cell clone used was GG33A that is restricted to CD1b molecule and specific 
for lipid antigen GM1. 
Every 3 weeks T cells need to be restimulated. T cell clones restimulation is 
done using irradiated PBMCs as feeder cells and the antigen phytohaemagglutinin 
(PHA) in medium containing rhIL-2. PBMCs are isolated following the protocol 
presented above. Then, PBMCs are ressuspended in culture medium (see 
appendix) at a concentration of 5 x 106 cells/mL and irradiated in a gamma 
irradiator (Gammacell 1000, Nordion) at 3000 rad. After the irradiation process, 
cells are washed twice with culture medium and once with PBS. PBMCs are 
counted and ressuspended in T cell culture medium with 2µg/mL of PHA (see 
appendix). The T cell clones to restimulate are in culture, at a concentration of 
approximately 1x106 cells/mL, 1mL per well. For restimulation, 1mL of irradiated 
PBMCs is added to each well containing T cells. Two wells have only irradiated 
PBMCs, to verify the efficacy of the irradiation process. If the irradiation is 
successful, all irradiated PBMCs should die approximately in 15 days. 
 
Lipid antigen presentation assays 
In these in vitro assays, dendritic cells are incubated with the lipid antigen 
and with T cell clones. T cell clones recognize the lipid antigen bound to CD1 at 
the cell surface of the dendritic cell, and when T cell clones bound to this complex 
are activated and start producing cytokines. The cytokines can be then detected, 
indicating the efficiency of the lipid antigen presentation. 
These in vitro assays were performed as previously described [48, 49]. 
Dendritic cells were collected, counted and resuspended in culture medium (see 
appendix) without iFBS at a concentration of 0.4x106 cells/mL. This medium does 
not contain iFBS to facilitate lipid antigen uptake by the dendritic cells. 20000 cells 
(50 µL of the solution of 0.4x106 cells) were added to each well of 96-well flat-
bottomed plate and incubated at 37ºC, 5% CO2.  
Then, antigen dilutions were performed. GM1 was initially diluted in a 
solution of chlorophorm:methanol (1:1) in a concentration of 10mg/mL. The lipid 
was diluted 4x in the activation volume, so a solution of 200µg/mL was necessary. 
Then, was dried under N2 and dissolved only in methanol to obtain the needed 
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concentrations, because chlorophorm is toxic for the cells. After this, the lipid 
antigen was sonicated for 3 min in a water bath sonicator. Eight serial dilutions of 
1:3 in duplicates were prepared in 50 µL of the culture medium with iFBS and 
added to the wells containing the dendritic cells. The lipid antigen concentrations 
tested were: 16.7; 5.6; 0.62; 0.07 µg/mL and a blank without antigen. Dendritic 
cells were incubated with the lipid antigen at 37ºC, 5% CO2 for 4 hours. In the 
meantime, the T cell clone was collected washed once with PBS and counted. 
100µL of the culture medium with 20% iFBS containing 100000 T cells were added 
per well. This medium has 20% iFBS to obtain a final concentration of 10% iFBS, 
since 100µL are added in a total final volume of 200µL. The T cell clone, dendritic 
cells and lipid antigen were incubated at 37ºC, 5% CO2 for 36 hours, to allow T 
cells activation and cytokine production. Then, plates were centrifuged at 1200 
rpm for 2 min and 150µL of the supernatant were collected and used for 
determination of cytokine concentration by ELISA. 
 
ELISA 
ELISA plates (MaxiSorp, Nunc) were coated with 50µL per well of purified 
anti-human GM-CSF (BVD2-23B6, Biolegend) at 4ºC, overnight. The coating 
solution was then removed and wells were washed once by adding 300µL of 
washing buffer, PBS, 0.05%Tween 20 (see appendix) to each well. Then the cells 
were blocked by adding 100µL of blocking buffer, PBS, 0.05% Tween 20, 1%BSA 
(see appendix) and incubated at room temperature for 1 hour. After this process, 
wells were washed twice and incubated with 50µL of the sample. In some wells, 
50µL of the standard rhGM-CSF were added in eight different concentrations, 
starting in 20 ng/mL (1:3 serial dilutions) in duplicates. After an incubation of 1 
hour and 30 min, wells were washed three times and 50µL of the biotinilated anti-
human GM-CSF antibody (BVD2-21C11, Biolegend) were added to each well. 
After 1 hour and 30 min, wells were washed again with washing buffer three times. 
Then for detection of the biotinilated antibody, 70µL of streptavidin conjugated with 
horseradish peroxidase from Invitrogen were added to each well and incubated for 
1 hour at room temperature, in the dark. Wells were washed four times, and after 
90µL of SigmaFastTM o-phenylenediamine dihydrochloride (OPD) from Sigma, a 
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substrate for the horseradish peroxidase, were added. The OPD reagent was 
SUHSDUHG DFFRUGLQJ WR WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV7KH UHDFWLRQ RFFXUUHG IRU
about 30 min, at room temperature, in the dark. Then the reaction was stooped 
adding 50µL of H2SO4. Absorbance was read at 490 nm on an ELISA plate reader 
(µQuant, Biotek). According to the rhGM-CSF standards, absorbance values were 
converted to cytokine concentration values. 
 
Statistical analyses 
Statistical analyses were made using the GraphPad Prism 5 software. 
Mean and standard deviation values were calculated and statistical significance 
ZDV DVVHVVHG E\ 6WXGHQW¶V 7-Test. P-values bellow 0.05 were considered 
significant. 
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4. Results 
 
Mucopolysaccharidosis type VI patients and control subjects characteristics 
In this study seven MPS VI patients and seven control subjects were 
analyzed.  The general characteristics of MPS VI patients, such as, sex, age, 
genetic mutations in ARSB gene and the date they started the enzyme 
replacement therapy, are described in Table 4. All the patients are currently under 
treatment. The control group of this study is composed by two males and five 
females, with ages between 15 and 40 years old. 
 
7DEOH  0XFRSRO\VDFFKDULGRVLV W\SH 9, SDWLHQWV¶ FKDUDFWHULVWLFV VH[ DJH
mutations and starting date of enzyme replacement therapy. 
 
Patient 
 
Sex 
 
Age 
 
Mutation 
 
ERT 
 
1 F 18 R315Q 2003 
2 M 20 R315Q 2003 
3 M 18 NA 2004 
4 F 4 NA 2010 
5 F 23 L72R 2003 
6 F 14 NA NA 
7 F 26 NA NA 
M ± male; F ± female; ERT ± enzyme replacement therapy; NA ± Not available 
 
 
The percentage of iNKT cells and their subsets are not altered in peripheral blood 
of Mucopolysaccharidosis type VI patients in comparison with control subjects 
 
In this study, peripheral blood iNKT cells were identified by flow cytometry, 
using an antibody anti-human CD3 and the human CD1d tetramer loaded with 
PBS57. The gating strategy used to identify the iNKT cells is exemplified in Figure 
6. First in this analysis the lymphocyte gate is defined using a side scatter and 
forward scatter cytogram, after this the T lymphocytes (CD3+) were selected using 
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a histogram, and the percentage of iNKT cells (CD1d-PBS57 tetramer positive 
cells) was determined inside the CD3+ gate.  
 
 
 
 
 
 
 
 
Figure 6. Flow cytometry analysis for iNKT cell frequency quantification. 
 
The percentage of iNKT cells among MPS VI patients and among control 
subjects is highly variable, as shown in Figure 7. Six MPS VI patients and seven 
control subjects were analyzed. The percentage of iNKT cells were slightly 
decreased in MPS VI patients, but this difference was not statistically significant. 
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Figure 7. iNKT cells frequency among T lymphocytes (CD3+) in MPS VI patients. 
iNKT cells were identified in the gate of CD3+ cells as positive for CD1d-PBS57 tetramer. 
Horizontal bars represent means. 
 
 
The percentage of iNKT cells activated (that express CD69) were also 
analyzed, and the results are shown in Figure 8. We found that some patients had 
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a more activated phenotype in comparison with controls, but in general the 
differences were not significant. Interestingly the two MPS VI patients with higher 
expression of CD69 in the iNKT cells are the two male patients analyzed.  
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Figure 8. The percentage of activated iNKT cells in MPS VI patients and in control 
subjects. Horizontal bars represent means. 
 
In humans, the iNKT cell population can be divided in three different 
subsets according to the expression of CD4 and CD8 molecules. These subsets 
are CD4+ (that only express CD4); CD8+ (that only express CD8) and CD4-CD8- 
(do not express neither of these molecules). The subsets were analyzed after 
selected the gate of iNKT cell population (Figure 9). 
 
 
 
 
 
 
 
 
 
Figure 9. Representative example of iNKT cell subsets frequency determined by flow 
cytometry. 
 
In the analyses of the three subsets of iNKT cell population, no alteration 
was found in their frequency between MPS VI patients and the control subjects 
(Figure 10). For the iNKT cells CD4+ subset we had a patient with a higher 
percentage of this subset, which is the younger patient analyzed with only 4 years 
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old. This patient had a 92.1% of CD4+ iNKT cells, and is also one of the patients 
with lower percentage of total iNKT cells. In the case of CD8+ iNKT cells 
percentage the patient that showed higher percentage was patient number 2.  
MPS VI Controls
0
20
40
60
80
100
%
 
iN
K
T 
CD
4+
MPS VI Controls
0
10
20
30
40
50
%
 
iN
K
T 
CD
8+
MPS VI Controls
0
20
40
60
80
%
 
iN
K
T 
D
N
A B
C
 
Figure 10. iNKT cell subsets frequency in MPS VI patients  and control subsets. 
Horizontal bars represent means. A ± iNKT CD4+ cell frequency; B ± iNKT CD8+ cell 
frequency; C ± iNKT DN cell frequency. 
 
The percentage of iNKT cells in peripheral blood is not altered overtime (one year) 
in patients with Mucopolysaccharidosis type VI  
 
For five of the patients it was possible to analyze the percentage of iNKT 
cells and the CD4+ iNKT cell subset twice with one year of interval. The results are 
described in Figure 11 and show that there is a slight decrease of the percentage 
of iNKT cells between the analyses made in 2011 and 2012 in three of the patients 
(Figure 11A) and for the other two patients the values keep stable. However even 
for the patients for which there is a small decrease in the percentage of iNKT cells, 
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patients that had higher iNKT cells levels maintained high levels and patients with 
lower levels maintained lower levels. The percentage of CD4+ iNKT cells in the 
MPS VI patients remained stable in the two analysis made, with the exception of 
the patient number three that had a slight increase (but maintained the same 
range level) in the percentage of this subset, results shown in Figure 11 (B). These 
small variations did not appear to be correlated with age or sex of the patients.  
2011 2012
0.00
0.05
0.10
0.15
0.20
0.25
1
2
3
4
5
%
 
iN
K
T 
c
e
lls
2011 2012
0
20
40
60
80
100
1
2
3
4
5
%
 
iN
K
T 
CD
4+
A B
 
Figure 11. Variation of iNKT cells over one year period (A) and their CD4+ subset (B) 
frequency in five MPS VI patients. 
 
T cells in Mucopolysaccharidosis type VI patients 
 
Total T lymphocyte population was analyzed too. This population was 
identified by the expression of CD3+ molecule and can be divided into two major 
subsets, the cytotoxic T cells (CD8+) and the helper T cells (CD4+). The naïve and 
memory subsets within T cells were also analyzed, these data are not shown here, 
because currently the age of the control subjects and the MPS VI patients are not 
matching and age clearly influences the naïve and memory subsets [50]. 
 
  
Table 5. The mean and standard deviation values of the percentage of T 
lymphocytes (CD3+), and their subsets (CD4+ and CD8+) in MPS VI patients and control 
subjects. 
Cells Patients  Controls  
T lymphocytes 78 ± 3 80 ± 6 
CD4 51 ± 8 51 ± 5 
CD8 23 ± 7 23 ± 4 
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The results described (Table 5) for T cells and their subsets showed no 
differences statistically significant. The values were very similar between MPS VI 
patients and control subjects.  
 
Alteration of the B cell population in Mucopolysaccharidosis type VI patients 
The B lymphocytes that are identified by the expression of CD19 and the 
NK cells, which express CD56 at the cell surface, were also analyzed. The results 
of B cells are shown in Figure 12, and for the NK cells in Figure 13. 
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Figure 12. Percentage of B cell population is higher in MPS VI patients. B cells were 
identified in the lymphocytes gate as cells positive for CD19. Horizontal bars represent 
means. Statistical significance was calculated by StudHQW¶V7WHVWS 
 
For the B cell population were found differences between control subjects 
and MPS VI patients that were statistically significant (p<0.05). The MPS VI 
patients have an increase of the percentage of B cells when compared with control 
subjects. 
MPS VI Controls
0
5
10
15
20
25
%
 
NK
 
Figure 13. Percentage of NK cells in MPS VI patients. NK cells were identified in the  
lymphocytes gate as cells positive for CD56 and negative for CD3. Horizontal bars represent 
means. 
* 
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In the case of NK cells no significant differences were found between MPS 
VI patients and control subjects (Figure 13). 
 
MPS VI dendritic cells phenotype 
 
Dendritic cells were generated in vitro from MPS VI patients and from 
FRQWURO VXEMHFW¶V PRQRF\WHV LVRODWHG IURP SHULSKHUDO EORRG 'HQGULWLF FHOOV ZHUH
differentiated from monocytes over 7 days in culture with GM-CSF and IL-4. After 
this, dendritic cells were analyzed by flow cytometry to confirm differentiation. For 
this study only 3 patients were analyzed, because of the low volume of blood 
received from the patients. Two control subjects were analyzed at the same time. 
To confirm differentiation the expression of CD80 and CD11c molecules were 
analyzed. In all the control subjects and MPS VI patients, dendritic cells had a 
CD80 and a CD11c expression compatible with dendritic cell differentiation (Figure 
14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Representative example of monocyte derived dendritic cells phenotype.  
A - CD80 cell surface expression; B ± CD11c cell surface expression. Cells were stained 
with anti-human CD80 and CD11c and analyzed by flow cytometry. The black line 
corresponds to unstained and blue line to stained sample. 
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The expression of CD80 was similar between MPS VI patients and control 
subjects (Figure 15). The three MPS VI patients showed similar values and when 
compared with the control subjects no differences were found. 
 
 
 
 
 
 
 
 
 
Figure 15. Histogram plots of CD80 expression at the cell surface of dendritic cells 
from control subjects and MPS VI patients. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
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However, for the expression of CD11c molecule, two of the MPS VI patients 
analyzed showed a decrease in comparison with control subjects (Figure 16). We 
can see for patient number 1 (Figure 16 A) and for patient number 2 (Figure 16 B) 
a decrease on the expression of CD11c molecule when compared with control 
subjects. 
 
 
 
 
 
 
 
 
Figure 16. Histogram plots of CD11c expression at the surface of dendritic cells from 
control subjects and MPS VI patients. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
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Concerning CD1a expression, one of the patients, patient number 1, 
showed similar values compared with control subjects (Figure 17 A). For the other 
two MPS VI patients, patient number 2 (Figure 17 B) and patient number 4 (Figure 
17 C) when compared with control subjects showed dendritic cells with a bimodal 
expression, with a population that had lower expression of CD1a.  
 
 
 
 
 
 
 
 
Figure 17. Histogram plots of CD1a expression at the cell surface of dendritic cells 
from MPS VI patients and control subjects. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
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In the case of CD1b molecule, the results showed no alterations in dendritic 
cell surface expression of this molecule in two patients (Figure 18). Patient number 
1 (Figure 18 A) showed a slight decrease in dendritic cell surface expression of 
CD1b.  
 
 
 
 
 
 
 
 
 
Figure 18. Histogram plots of CD1b expression at the cell surface of dendritic cells 
from MPS VI patients and control subjects. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
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No differences were found in dendritic cell surface expression of CD1c 
molecule. The results obtained for the three MPS VI patients were very similar 
among them and when compared with the control subjects (Figure 19).  
 
 
 
 
 
 
 
 
Figure 19. Histogram plots of CD1c expression at the cell surface of dendritic cells 
from MPS VI patients and control subjects. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
 
 
In this study, Group II CD1 molecules were not tested. Justified by the fact 
that monocyte derived dendritic cells cultured in media containing FBS do not 
express CD1d at the surface in amounts detectable by flow cytometry [51]. 
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The same MPS VI patients and control subjects were analyzed for cell 
surface expression of MHC class I (HLA-ABC) and MHC class II (HLA-DR). Figure 
20 shows the results for HLA-ABC, no alterations were found in the dendritic cell 
surface expression of this molecule in two MPS VI patients tested, patient number 
1 (Figure 20 A) and patient number 2 (Figure 20 B) when compared with control 
subjects. In patient number 4 (Figure 20 C) two populations of dendritic cells can 
be identified by the expression of HLA-ABC, a population similar to the other 
subjects and a population with higher expression of HLA-ABC.  
 
 
 
 
 
 
 
 
Figure 20. Histogram plots of HLA-ABC expression at the cell surface of dendritic 
cells from MPS VI patients and control subjects. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
 
 
 
HLA-ABC 
HLA-ABC HLA-ABC 
%
 o
f 
M
a
x
 
%
 o
f 
M
a
x
 
%
 o
f 
M
a
x
 
C 
B A 
 39 
 
In the case of HLA-DR two of the MPS VI patients, patient number 1 (Figure 
21 A) and patient number 2 (Figure 21 B) had a slight decrease in the cell surface 
expression of this molecule compared with the control subjects. Patient number 4 
(Figure 21 C) showed a bimodal expression of HLA-DR. 
 
 
 
 
 
 
 
 
 
Figure 21. Histogram plots of HLA-DR expression at the cell surface of dendritic 
cells from MPS VI patients and control subjects. Flow cytometry analyses of dendritic cells 
differentiated from monocytes was performed at day 7. A ± Patient number 1; B ± Patient 
number 2; C ± Patient number 4. 
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Lipid antigen presentation to T cells in Mucopolysaccharidosis type VI patients 
 
The capacity of dendritic cells from MPS type VI patients to present lipid 
antigens and consequently activate T cells in comparison to control subjects was 
assessed using an in vitro system of lipid antigen presentation. For this part of the 
study only three patients were analyzed for one of the CD1 isoforms (CD1b), due 
to a limitation in this study that is the amount of peripheral blood sample collected 
from the patients that is generally small and so a few cells were collected for 
culture. Dendritic cells were derived from monocytes, and when differentiated were 
incubated with different concentrations of lipid antigen (GM1) for 4 hours. Then, a 
T cell clone restricted to CD1b molecule (GG33A) was added and incubated for 36 
hours, to allow activation of the T cell clone and consequent cytokine production. 
ELISA was performed to determine cytokine concentration on the supernatant 
collected. The efficiency of the lipid antigen presentation by CD1b molecule is 
related to the amount of cytokine produced.  
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Figure 22. GM-CSF production by T cell clone GG33A activated with dendritic cells 
from four control subjects and three MPS VI patients. A ± patient number 1; B ± patient 
number 2; C ± patient number 7. Dendritic cells were challenged with GM1 for 4h and then 
the T cell clone GG33A was added to the culture. 36h later supernatant was collected and 
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cytokine concentration determined by ELISA. The values represent means and standard 
deviation. 
 
In the presentation of GM1 by CD1b, the three MPS VI patients showed a 
similar capacity for antigen presentation (this was assessed measuring the 
concentration of cytokine produced by the T cell clone when incubated with the 
dendritic cells plus the lipid antigen) these results are in Figure 22. Patient number 
7 and the controls 3 and 4, as shown in Figure 22 C had lower cytokine production 
in comparison with the other subjects analyzed. This could be explained by the 
fact that patient number 7 and controls 3 and 4 were analyzed in a different day, 
and so the T cell clone used could be less responsive. 
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5. Discussion  
Lysosomal storage diseases are metabolic disorders, characterized by the 
accumulation of biological materials in lysosome. This accumulation causes the 
impairment of lysosome, which is an intracellular compartment important for lipid 
antigen presentation and consequently important for the CD1 restricted lipid 
specific T cells. So emerged the hypothesis that patients with LSDs could have 
lipid antigen presentation and CD1 restricted lipid specific T cells affected. Several 
of the studies regarding CD1 restricted T cells were made in iNKT cells, because 
they are more easily identified. The percentage of the iNKT cells or their subsets  
was described to be altered in a variety of conditions, such as HIV infections [34], 
during Mycobacterium infections [52], during rejection of kidney transplants [53], 
and in cases of advanced cancer [54]. Other studies found a decrease in the iNKT 
cells percentage in the thymus and at the periphery in mouse models of several 
LSDs [37-43]. For some of these LSDs the reduced number of iNKT cells in 
mouse models was associated with deficient lipid antigen presentation [37, 38, 40, 
41, 43, 46].  In humans Fabry, Gaucher and Niemann-Pick type C diseases were 
tested and no alterations in the percentage of total iNKT cells were found [42, 44, 
45, 55]. 
The aim of our work was to study the lymphocyte family including B cells 
and T cells. And inside the T cells the CD1 restricted lipid specific T cells, 
analyzing the percentage of iNKT cells in MPS VI patients and testing the capacity 
of dendritic cells from the MPS VI patients to present lipid antigens to lipid specific 
T cells.  
The iNKT cells percentage was highly variable among the MPS VI patients 
analyzed, similar to the variation that we and others have found on healthy 
subjects [31]. As previously described for other LSDs, such as Fabry, Gaucher 
and Niemann-Pick type C [42, 44, 45, 55] no differences statistically significant 
were found in the percentage of iNKT cells between the MPS VI patients and 
control subjects analyzed.   
iNKT cells in humans can be divided in three different subsets, the CD4+ 
subset (only express CD4), the CD8+ subset (only express CD8) and DN (do not 
express neither of them). No significant differences in the percentage of the three 
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subsets between MPS VI patients and control subjects were found. Although 
recently our laboratory found in two sphingolipidoses alterations in the iNKT 
subsets. In Fabry disease patients a decrease in the percentage of CD4+ iNKT 
cells and in Gaucher diseases patients an increase of this subset was found 
(Pereira et al unpublished results). Therefore the results obtained with MPS VI 
patients suggest that the alterations in the iNKT cells present in Fabry and 
Gaucher diseases are related to the specificity of the material stored rather than 
being associated with a general lysosomal dysfunction. 
 One of the MPS VI patients analyzed, the youngest showed a percentage 
of iNKT cells CD4+ very high (92.1%) compared with others MPS VI patients and 
this patient was also one of the MPS VI patients with lower percentage of iNKT 
cells (0.013%). This is in agreement with results previously described by Montoya 
et al, where they saw that iNKT cells percentage have an inverse correlation with 
the percentage of the CD4+ subset cells [56].  
Five of the MPS VI patients were analyzed twice (2011 and 2012). The 
results showed no significant differences in the percentage of the iNKT cells and 
their CD4+ subset between the two analyses. Longitudinal studies were already 
assessed in Fabry disease patients and the results showed some alterations on 
WKHSHUFHQWDJHRIL1.7FHOOVLQSDWLHQWVXQGHU(57KRZHYHUWKHSHUFHQWDJHGRQ¶W
follow an increase or decrease pattern. So no significantly differences were found 
in the percentage of iNKT cells overtime in Fabry disease patients [57], according 
to the results presented here for MPS VI patients. We show that iNKT cells were 
stable over a period of one year in MPS VI patients under ERT. 
For lipid antigen presentation assays we used DCs as APCs, a T cell clone 
restricted to CD1b molecule (GG33A) and a lipid antigen (GM1). For all the MPS 
VI patients analyzed were not found differences between them and the control 
subjects using CD1b molecule. These results are in agreement with previous 
results obtained in Fabry disease patients [57] and in Niemann-Pick disease type 
C [55]. In MPS patients this studies were accessed for the first time. 
During this thesis I tried to develop a method to assess GAGs accumulation 
in few cells, to investigate the accumulation of GAGs in MPS VI patients DCs. To 
develop the method I used a patient fibroblasts cell line that was previously 
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described to accumulate GAGs and used Alcian blue cell staining followed by 
observation under optical microscopy. Alcian blue stains mixtures of sulfated 
GAGs, but does not allow distinguish between different types of GAGs [58]. This 
method turned out to be not sensible enough. Currently we are establishing a 
technique using Lysotracker, to evaluate the intralysosomal accumulation of 
undegraded macromolecules in DCs of LSDs patients by flow cytometry. 
Lysotracker was used before to measure the accumulation of cholesterol and 
gangliosides in cells of Niemann Pick type C2 mouse models [46] and in Niemann 
Pick type C1 patients [55]. 
)RU WKH VWXG\ RI '&V SKHQRW\SH 036 9, SDWLHQWV¶ GHQGULWLF FHOOV ZHUH
generated from peripheral blood monocytes and used as APCs. We found small 
alterations in the DCs phenotype, but more subjects need to be included in the 
study before definitive conclusions can be drawn. We observed that expression of 
CD80 was similar between controls and MPS VI patients, however for CD11c 
expression two of the MPS VI patients shown a slightly decrease expression of 
this molecule when compared with control subjects. Group I CD1 molecules, was 
also analyzed and in this group CD1b and CD1c molecules expression were 
similar between MPS VI patients and control subjects, for CD1a molecule we 
found for the MPS VI patients two populations of DCs, one that express more 
CD1a and one that express less, this DCs that express low levels of CD1a can be 
in a different step of differentiation, supported by the notion that differentiation of 
CD1a- to CD1alow to CD1ahigh cells represent consecutive steps of DCs 
differentiation from monocytes [59]. CD1d was not analyzed due to the dendritic 
cells cultured in media containing FBS do not express CD1d at the surface in 
amounts detectable by flow cytometry [51]. In this work we analyze also the MHC-
class I and MHC-class II molecules. For the HLA-ABC (MHC-class I) expression 
only one of the MPS VI patients (the youngest) showed alterations that was once 
again the observation of two populations of DCs (one that express more and one 
that express less HLA-ABC). The HLA-DR (MHC-class II) expression was altered 
in all three MPS VI patients when compared with the control subjects, the patients 
shown a slight decrease in the expression of this molecule, with the exception of 
the patient that shown a bimodal expression. Some of this alterations could be 
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related with a fact documented, that gangliosides can inhibit the differentiation of 
DCs from monocytes and influence the DCs phenotype [60]. It was reported 
previously that MPS VI feline models exhibit accumulation of both GM2 and GM3 
gangliosides [61]. So this could be affecting the DCs phenotype of MPS VI 
patients and highlight the relevance of continuing the study of the DCs phenotype 
in these patients. 
During this study T cell and B cell populations were also analyzed; T cell 
population can be divided in two subsets, the cytotoxic T cells (CD8+) and the 
Helper T cells (CD4+:HGRQ¶W IRXQG VLJQLILFDQWO\ GLIIHUHQFHV EHWZHHQ 036 9,
patients and control subjects for T lymphocytes and their subsets. However for B 
cell population we found an increase of the percentage of these cells in MPS VI 
patients when compared with control subjects. Our results for B cells are in 
agreement with previous work of Rozenfeld et al, where they described a 
significantly higher percentage of B lymphocytes in Fabry disease patients, both 
under ERT or without enzymatic treatment, compared with control subjects [44]. 
All the MPS VI patients that were studied in this work were under ERT. It is known 
that some patients develop antibodies against the infused enzyme [62]. Therefore 
the increase percentage of B cells may be related with chronic activation of the B 
cells caused by ERT. However, other yet not-identified mechanism could be 
responsible for the increase in the percentage of B cells. 
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6. Final considerations 
This study allowed the characterization of the T and B lymphocytes in MPS 
VI patients. For the percentage of total iNKT cells, as the same as for the iNKT 
cells subsets no alterations were found in MPS VI patients, contrary to that was 
found for sphingolipidoses. The longitudinal study shows that iNKT cells from MPS 
VI patients under ERT continuo stable over a period of one year. Regarding lipid 
antigen presentation no alterations on the capacity of DCs from MPS VI patients to 
present lipid antigens by CD1b molecule were found. For the DCs phenotype, 
small alterations were found, but more subjects need to be included in the study 
before conclusions can be drawn. B lymphocyte population were found to be 
increased in patients with MPS VI , as previously described for Fabry disease by 
Rozenfeld et al [44]. With our studies regarding T cells, B cells and antigen 
presenting assays, we hope to contribute for the better understanding of this 
disease and the effect of their metabolic defects in immune system. 
Since MPS VI is rare disease and we work with patients, some limitations 
appear in the course of the work. Such as, few patients that have this disease, 
small amount of blood samples and consequently few cells available, that 
sometimes, does not allow make all the assays in the same experiment. Other 
limitation of this work and of this thesis in particular was that we receive the blood 
samples from the MPS VI patients only in May. Age matching is another problem 
in our work, because some of the MPS VI patients are pediatric, and the controls 
that we obtain from the blood bank are all adults. This is still an ongoing project 
and we are trying at this time make a protocol to obtain youngest controls, to make 
possible an age match in our work. And we want to get access to more MPS VI 
patients in order to draw more conclusions about the DCs phenotype. 
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 Appendix 
Composition of the solutions used in the experimental work: 
 
PBS 10x 
For a total volume of 1000mL, add: 
80g of NaCl 
2g of KCl 
6.09g of Na2HPO4 
2g KH2PO4 
to H2O 
 
Adjust pH to 7.3 
 
PBS 1x 
For 1000mL, add 100mL of PBS 10x to 900mL of H2O. 
 
ACK lysis solution 
For a final volume of 500mL, add: 
4.15g of NH4Cl 
0.5g of KCO3  
to H2O 
 
Adjust pH to 7.2 
 
Flow cytometry solution (PBS 0.2% BSA 0.1%NaN3) 
For 100mL of solution, add: 
0.2g of bovine serum albumin (BSA) 
0.1g of NaN3 
to PBS 1x 
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MACS buffer 
For a final volume of 50mL, add 5mL of PBS, 2 mM EDTA, 5% BSA to 45mL of 
PBS 2 mM EDTA 
o PBS, 2 mM EDTA 
      2mL of EDTA 0.5 M 
      50mL of PBS 10x 
      448mL of H2O 
 
o PBS, 5% BSA, 2 mM EDTA 
       Add 2.5g of BSA to 50mL of PBS, 2 mM EDTA 
 
PBS 25% HS 
For a final volume of 1mL, add 250µL of human serum to 750µL of PBS 1x 
 
PBS 1% formaldehyde 
For a final volume of 4 mL, add 1mL of 16% formaldehyde to 3mL of PBS 1x 
 
Culture medium 
500mL RPMI 1640 (Invitrogen) 
5mL of non essential aminoacids (Invitrogen) 
5mL of kanamycin (Invitrogen) 
5mL of sodium pyruvate (Invitrogen) 
50mL (10%) of inactivated fetal bovine serum (Invitrogen) 
 
 
Dendritic cell culture medium 
 
Culture medium plus 25ng/mL of rhGM-CSF (immunoTools) and rhIL-4 
(immunoTools) 
 
 
 
 
 
 52 
 
T cell culture medium 
 
500mL RPMI 1640 (Invitrogen) 
5mL of non essential aminoacids (Invitrogen) 
5mL of kanamycin (Invitrogen) 
5mL of sodium pyruvate (Invitrogen) 
25mL of human serum (Invitrogen) 
500µL of rhIL-2 (stock 10000U/mL) (Invitrogen) 
 
 
Washing buffer (ELISA) 
PBS 0.05% Tween20 
 
For 100mL, add 50µL of Tween20 to PBS 1x 
 
 
Blocking buffer (ELISA) 
PBS 0.05% Tween20, 1% BSA 
 
For a final volume of 100mL, add 50µL of Tween20 and 1g of BSA to PBS 1x 
 
 
 
 
 
